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  T
ie (tyrosine kinase with 
immunoglobulin-like loop 
and epidermal growth factor 
homology domains) represents a 
novel class of receptor tyrosine kinases 
that are mostly expressed by vascular 
endothelial cells. There are currently 
two known members in this class: 
Tie1 (also described as Tie) and Tie2 
(also known as Tek; reviewed in [1]). 
During embryonic development, 
endothelial cells express both Tie1 
and Tie2 receptors. Tie2 is also 
expressed in quiescent endothelial 
cells in adult tissues. Unlike Tie1, 
Tie2 has well-described ligands called 
angiopoietins. Of the four currently 
known angiopoietins (Ang1–4), the 
best characterized are angiopoietin-1 
(Ang1) and angiopoietin-2 (Ang2). 
    The functional consequences of 
Ang/Tie2 signaling have been well 
established through genetic loss-
of-function and gain-of-function 
experiments in animals and cultured 
human endothelial cells. According 
to these functional studies, Ang1 is an 
agonist ligand that activates Tie2, thus 
controlling endothelial cell survival and 
vessel maturation associated with the 
quiescent nonproliferating endothelial 
cell phenotype. The functions of Ang2 
appear more complex. Ang2 binds to 
the Tie2 receptor, but acts as a non-
signal-transducing Tie2 antagonist 
ligand that blocks Ang1/Tie2 signaling 
and acts as a blood vessel–destabilizing 
cytokine. However, high concentrations 
of Ang2 or prolonged exposure of 
endothelial cells to Ang2 have been 
shown to activate Tie2 signaling, 
although the mechanisms of this 
paradoxical agonist activity of Ang2 are 
not well understood [1]. 
    The Role of Angiopoietins 
in Angiogenesis
    Angiopoietins are critically involved in 
physiological and pathological (e.g., 
tumorigenesis) blood vessel formation, 
or angiogenesis (reviewed in [2]). 
Neither Ang1 nor Ang2 can trigger an 
angiogenic response alone, but both 
enhance vascular endothelial growth 
factor (VEGF)–induced angiogenesis. 
Ang1 signaling via Tie2 promotes vessel 
maturation and quiescence, whereas 
Ang2 blocks Ang1/Tie2 signaling, 
and this leads to either angiogenesis 
or vessel regression and apoptosis, 
depending on the presence of VEGF or 
other angiogenic factors. 
    The current working hypothesis 
is that new vessel formation requires 
the temporal and spatial integration 
of signals originating from both 
Tie2 and VEGF receptors. The ﬁ  rst 
step is an upregulation of Ang2 that 
blocks the stabilizing action of Ang1 
on the vasculature. This then allows 
VEGF and other growth factors to 
promote endothelial cell migration, 
proliferation, and organization into 
new vessels. Once the new vessels have 
been formed, Ang1 levels increase 
and Ang2 levels decrease, allowing the 
formation of a mature vasculature. This 
hypothesis suggests that the Ang1/
Ang2 ratio, more than absolute levels of 
either ligand, is critical for determining 
the endothelial cell phenotype [2].
  Angiopoietins  and  Inﬂ  ammation
    The expression and phosphorylation 
of the Tie2 receptor in the normally 
quiescent mature vasculature suggests 
that Ang1/Tie2 signaling not only 
plays a role in angiogenesis but is also 
actively involved in the formation 
and maintenance of the vascular 
endothelial barrier. Indeed, the 
binding of Ang1 to Tie2 stabilizes 
in vitro endothelial cell interactions 
with the extracellular matrix and 
junctional proteins, and enhances 
barrier function [3]. For example, 
Ang1 has been shown to protect 
the adult vasculature against plasma 
leakage induced by VEGF [4] by 
inhibiting the calcium inﬂ  ux into the 
cells [5]. In addition, the activation of 
Ang1/Tie2 signaling attenuates H2O2-
induced apoptosis by activating the 
phosphoinositol 3-kinase/Akt pathway 
[6]. These results suggest that Ang1 has 
anti-inﬂ  ammatory properties. 
    A recent study showed that the 
adenoviral gene transfer of Ang1 can 
protect mice against endotoxic shock 
induced by   Escherichia coli   endotoxin, 
and is associated with an improvement 
in hemodynamic function, reduced 
lung injury, and a lower expression of 
inﬂ  ammatory adhesion molecules [7]. 
A similar protective function of Ang1 
was also observed in mice that had 
increased brain barrier permeability 
due to overexpression of VEGF [8]. 
In contrast, Ang2 appears to cause 
vascular leakage. It stimulates in vivo 
within 30 minutes the extravasation 
of ﬂ  uid in the mouse paw [9]. When 
submaximal doses of Ang2 and VEGF 
were administered at the same time 
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“Can soluble Ang2 
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in the mouse paw, their effects were 
additive, suggesting that the two factors 
act independently [9]. Furthermore, 
expression proﬁ  ling studies have 
shown that endothelial cells are the 
primary source of Ang2 [10], and that 
Ang2 levels can be transcriptionally 
and post-transcriptionally regulated 
by hypoxia or exposure to growth 
factors, such as VEGF or platelet-
derived growth factor (PDGF) [11]. In 
addition, Ang2 protein is stored inside 
endothelial cells and can be secreted 
within minutes after stimulation by 
thrombin or histamine [12]. These 
ﬁ  ndings indicate that Ang2 is not only 
a regulator of angiogenesis and vessel 
maturation but is also involved in rapid 
vascular homeostatic reactions such as 
inﬂ  ammation and coagulation. 
    A New Study: The Role of Ang2 
in Acute Lung Injury
    In a new   PLoS Medicine   study, Samir 
Parikh and colleagues [13] describe 
a new, important role for Ang2 in 
acute lung injury. In a series of elegant 
and complementary human and 
mouse in vivo and in vitro studies, 
the investigators demonstrate that 
circulating Ang2 is elevated in humans 
with sepsis and impaired oxygenation. 
Furthermore, their study shows that 
the serum of these patients disrupts in 
vitro the endothelial architecture, an 
effect that correlates with the serum 
level of Ang2 and that can be reversed 
by the addition of Ang1. These results 
suggest that the presence of Ang2 in 
serum is at least in part responsible for 
compromising the barrier function of 
the vascular endothelium in acute lung 
injury from sepsis. 
    Additional in vitro experiments 
demonstrated that Ang2 alone can 
replicate the effect of human septic 
serum on endothelial structure, 
and that it promotes endothelial 
hyperpermeability via Rho-kinase and 
myosin light chain kinase activation. 
Similar effects were observed when 
Tie2 levels were reduced with 
Tie2 small interfering RNA. These 
results suggest that Tie2 signaling is 
constitutively active in endothelial 
cells and that the addition of Ang2 
blocks Tie2 signaling by inhibiting 
Tie2 phosphorylation, leading in turn 
to Rho-kinase and myosin light chain 
kinase activation and disruption of the 
endothelial monolayer. A ﬁ  nal set of in 
vivo studies demonstrated that systemic 
administration of Ang2 directly 
provokes vascular hyperpermeability 
and pulmonary edema in healthy adult 
mice. 
  Unanswered  Questions
    Despite the importance of these results, 
several questions about the role of 
Ang2 in acute lung injury remain 
unanswered. First, as previously shown 
for angiogenesis, the Ang1/Ang2 
ratio may be more important than the 
absolute Ang2 levels for determining 
the effect of Tie2 signaling on 
endothelial cell permeability. Parikh 
and colleagues’ study supports this 
hypothesis because recombinant Ang1 
was able to reverse the permeability 
effect of human septic serum 
containing high levels of Ang2 on 
quiescent human vascular endothelial 
cells. 
    Second, it remains unclear whether 
Ang2 only acts as an antagonist of 
the Tie2 signaling or whether it has 
agonist Tie2 effects on the pulmonary 
vasculature of patients with acute lung 
injury. Previous studies have reported 
that Tie2 mRNA and protein are 
highly expressed in the lungs [14], 
indicating a potential role for this 
pathway in controlling lung endothelial 
permeability. Furthermore, Ang2 
has been shown to have Tie2 agonist 
properties in the presence of other 
angiogenic factors such as VEGF [10], 
and high plasma levels of VEGF have 
been reported in patients with sepsis 
and correlate with increased vascular 
permeability [15]. Increased VEGF 
gene and protein expression has 
also been associated with ischemia-
reperfusion lung injury [16]. 
    Third, another intriguing question 
is which organs or cell types are 
responsible for elevated serum Ang2 in 
patients with severe sepsis. Is elevated 
Ang2 a manifestation of a localized 
increase in Ang2 production in the 
lungs? Or is increased Ang2 production 
a universal response of the vascular 
system during sepsis since sepsis affects 
the entire vasculature indiscriminately? 
If the latter is the case, vascular 
leakiness caused by Ang2 in severe 
sepsis may not be unique to the lungs, 
but may be a systemic phenomenon 
that affects other vital organs, including 
the brain. 
    Fourth, the question, “Can soluble 
Ang2 serve as a biomarker of acute 
lung injury?” remains an open one. 
A clinically useful marker should 
have a high positive predictive 
value in patients who are at risk 
for the syndrome but have not yet 
developed symptoms. Furthermore, 
a suitable biomarker should also be 
highly discriminative in predicting 
mortality in these patients. Although, 
as acknowledged by the authors, a 
much larger clinical study would be 
required to deﬁ  nitively conclude that 
the serum level of Ang2 is a valid 
biomarker to predict subsequent acute 
lung injury, the clinical data collected 
by Parikh and colleagues are not very 
encouraging. In this small cohort of 
patients, serum Ang2 levels reach their 
peak only at the same time as the nadir 
of the PaO2/FiO2 ratio. Furthermore, 
there was no difference in serum levels 
of Ang2 between patients who died and 
patients who recovered. 
  Conclusion
    In summary, Parikh and colleagues 
have provided important new insights 
regarding the mechanisms that control 
lung vascular permeability in patients 
with acute lung injury. They have 
demonstrated that Ang2, one of the 
known ligands of the Tie2 receptor, 
has a signiﬁ  cant role in increasing 
vascular permeability in patients with 
acute lung injury. As with all interesting 
discoveries, their study also raises many 
questions, and makes it clear that more 
work is needed to understand the 
complexity of the control of the lung 
vascular permeability in vivo under 
pathological conditions, such as acute 
lung injury.   
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